[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507310":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":21,"responsibleParty":45,"collaborators":47,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":7,"studyType":65,"phases":7,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Katharina Timper, Prof.","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+41613285742","katharina.timper@usb.ch",{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},"Valerie Mettraux","+41613285520","valerie.mettraux@usb.ch",[22],{"facility":23,"status":24,"city":25,"state":7,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"University Hospital Basel","RECRUITING","Basel","4031","Switzerland","CH",{"type":30,"coordinates":31},"Point",[32,33],7.57327,47.55839,{"lat":33,"lon":32},[36,38,40,41,43],{"name":10,"role":14,"phone":37,"phoneExt":7,"email":16},"+4161 328 57 42",{"name":18,"role":14,"phone":39,"phoneExt":7,"email":20},"+4161 328 55 20",{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"name":18,"role":42,"phone":7,"phoneExt":7,"email":7},"SUB_INVESTIGATOR",{"name":44,"role":42,"phone":7,"phoneExt":7,"email":7},"Lolita Matiashova, Dr. med.",{"type":46,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[48],{"name":49,"class":6},"University of Zurich","100507310","novel-targetable-biomarkers-in-anorexia-nervosa-100507310",false,"NCT05885724","Novel Targetable BIOmarkers in ANorexia NervosA","Novel Targetable BIOmarkers in ANorexia NervosA - BIOANNA","BIOANNA","N=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive type, non-exercising subtype\n\nInclusion criteria:\n\n* Age 18-60 years\n* Written informed consent\n* BMI 10-16 kg\u002Fm2\n\nN=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive type, exercising subtype will be included in this study.\n\nInclusion criteria:\n\n* Age 18-60 years\n* Written informed consent\n* BMI 10-16 kg\u002Fm2\n\nN=16 control participants, sex- and age-matched to the individual anorexia nervosa patients.\n\nInclusion criteria:\n\n* Age 18-60 years\n* Written informed consent\n* BMI 19-24.9 kg\u002Fm2\n\nExclusion Criteria:\n\n* Use of antibiotics within the last 31 days\n* Current illicit drug abuse including daily marijuana or CBD (cannabidiol) consumption (≤ 24 g of alcohol per day allowed)\n* Any kind of severe chronic disease other than AN (e.g. active cancer disease)\n* Severe renal impairment (e.g. estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002Fm2) if resulting from another disease than AN\n* Known liver cirrhosis or other severe liver impairment if resulting from another disease than AN\n* Acute upper respiratory tract infection within the last 31 days\n* Uncontrolled dysthyroidism\n* Uncontrolled hypertension\n* Current pregnancy\u002Flactation or current treatment for in vitro fertilization\n* Inability to understand the study information, to sign the consent form and to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.",true,"ALL","18 Years","60 Years",{"count":63,"type":64},32,"ESTIMATED","OBSERVATIONAL","The overall aim of this present study is to evaluate Growth Differentiation Factor-15 (GDF-15) and inflammatory cytokines as a possible novel and readily treatable target for the successful therapy of Anorexia Nervosa (AN). Therefore, GDF-15, neuronal and glial damage markers such as Neurofilament light chain (Nfl) and Glial fibrillary acidic protein (GFAP) and cytokines (such as Tumor necrosis factor alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin 1β (IL-1β) levels will be assessed in the serum as well as in the cerebrospinal fluid of patients with diagnosed restrictive AN with and without exercising behavior compared to sex- and age-matched healthy controls to consolidate previous findings and to identify the main site of production of GDF-15 and cytokines in AN.",[68,69],"Anorexia Nervosa","Anorexia Nervosa Restricting Type",[71,72,73,74,75],"exercising subtype","non-exercising subtype","Neurofilament light chain","Glial fibrillary acidic protein","Growth Differentiation Factor-15","2024-12-06",{"date":78,"type":79},"2024-12-12","ACTUAL",{"date":81,"type":79},"2023-05-01",{"date":83,"type":64},"2025-04-30",{"name":5,"class":6},1]